PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Cancer Res. Author manuscript; available in PMC 2010 August 15.
Published in final edited form as:
PMCID: PMC2766346
NIHMSID: NIHMS131002

Small Integrin Binding Proteins as Serum Markers for Prostate Cancer Detection

Abstract

Purpose

The SIBLING (Small Integrin-Binding LIgand N-linked Glycoprotein) gene family includes bone sialoprotein (BSP), dentin matrix protein-1 (DMP1), dentin sialophosphoprotein (DSPP), matrix extracellular phosphoglycoprotein (MEPE), and osteopontin (OPN). Previous studies have separately reported elevated expression of BSP, OPN or DSPP in prostate tumor paraffin sections. We hypothesized that SIBLINGs may be informative serum markers for subjects with prostate cancer.

Methods

Expression levels of SIBLINGs in biopsies of normal tissue and tumors from prostate were determined by cDNA array and by immunohistochemical staining with monoclonal antibodies. Competitive ELISAs for measuring total BSP, DSPP, MEPE and OPN were applied to a test group of 102 subjects with prostate cancer and 110 normal subjects and a validation group of 90 subjects.

Results

BSP, DMP1, DSPP and OPN exhibited elevated mRNA expression and protein levels in biopsies. BSP, DSPP and OPN were elevated in serum from prostate cancer subjects, with serum DSPP exhibiting the greatest difference, yielding an area under the receiver operator characteristic curve value of 0.98. Serum BSP and OPN levels were significantly elevated only in late stages, while DSPP was significantly elevated at all stages. Optimal serum value cut-off points derived for BSP, OPN and DSPP were applied as a validation test to a new group of 90 subjects and DSPP yielded a sensitivity of 90% and a specificity of 100%.

Conclusion

Of the SIBLING gene family members, DSPP appears to be a strong candidate for use in serum assays for prostate cancer detection.

Introduction

Prostate cancer is the leading cancer diagnosed among men in the United States (1). Detection is currently based on symptom presentation, physical examination (including a digital rectal exam, DRE), measuring serum levels of prostate-specific antigen (PSA) and biopsy. PSA measures have a significant rate of false positive test results (the PSA is elevated but no cancer is present) that often result in additional medical procedures, significant financial costs, and mental stress (2, 3). Furthermore, neither DRE nor PSA detect early tumors and they are sometimes uninformative in terms of predicting disease progression. Biopsies performed for confirmation of abnormal test results, to follow disease progression, or response to treatment can have side-effects that impact profoundly upon the quality of life (4).

We have been studying members of a gene family (termed SIBLINGs for Small Integrin-Binding LIgand N-linked Glycoproteins) that are aligned head-to-tail in tandem on human chromosome 4 and share: an abundance of acidic amino acids; the integrin-binding tripeptide, RGD; similar post-translational modification motifs (e.g. casein kinase phosphorylation and various glycosylation events); and at least one site of controlled proteolysis (5). SIBLINGs are normally expressed in skeletal tissues as well as metabolically active ductal epithelial cells (6), however, one or more are often induced in many different cancers (7). To date, at least three SIBLINGs (BSP, DMP1 and OPN) have been shown to bind and modulate specific matrix metalloproteinase (MMP) activities through both the activation of the latent pro-enzyme and reactivation of tissue inhibitor of matrix metalloproteinase (TIMP)-inhibited MMP (8, 9). MMPs have a well defined role in tumor angiogenesis, progression and metastasis (10). The biological activities of SIBLINGs and MMPs are consistent with a role for SIBLINGs in early tumor progression. This biological plausibility suggests that the levels of these proteins in blood may be used not only as adjuncts to conventional detection of prostate cancer, but also as serological markers for prostate cancer progression (5). A confounding facet of prostate cancer is the variable nature of progression (growth rate, metastasis, etc.) and the absence of non-invasive markers that consistently track with progression. The characterization of novel serum markers whose levels correlate with disease progression has the potential to benefit individuals with prostate cancer across the spectrum: from early detection; to monitoring disease progression and response to therapy.

Methods

Sample recruitment

Normal subjects (n = 110) were obtained under IRB approved protocols from the Johns Hopkins Bayview Medical Center General Clinical Research Center (JHBMC). The JHBMC normal group was obtained from an existing serum bank using samples from which all patient identifiers were removed. For this study, inclusion criteria as a normal serum donor included measures within the normal range for fasting glucose (< 100 mg/dl), TSH (0.5 - 2.1 mIU/mL), BMI (20 - 25 kg/m2) as well as a physical assessment by a physician. Exclusionary criteria included a previous history of hypertension, heart disease, diabetes mellitus, renal or hepatic dysfunction, cancer, or any chronic inflammatory condition (e.g., rheumatoid arthritis). Prostate cancer sera (n = 102) and tissue biopsies from subjects recently diagnosed with prostate cancer, prior to initiation of treatment, were obtained through commercial biorepositories (East Coast Biologics, Inc., NorthBerwick, Maine; Promedx, Inc., Norton, MA; and LifeSpan BioSciences Inc. Seattle, WA). An additional group of 90 serum samples (30 normal and 60 with prostate cancer) whose PSA values had already been determined, was obtained through the Department of Urology, at Johns Hopkins University for assay validation testing.

SIBLING probes and prostate cancer array analysis

A cancer profiling array (Clontech, Palo Alto, CA) containing normalized cDNA from tumor and corresponding normal tissues from 4 individual patients with prostate cancer was employed to screen for SIBLINGs as previously described (7). Briefly, several cancer-profiling arrays were hybridized in ExpressHyb hybridization solution (Stratagene, Cedar Creek, TX) with 32P-labeled cDNA probes for specific SIBLINGs as per the manufacture's instructions. Washed membranes were quantified by exposure to PhosphorImager screens for up to 24 hours and the exposed screen analyzed on a Molecular Dynamics PhosphorImager (GE Healthcare Bio-Sciences Corp, Piscataway, NJ) using the manufacturer's ImageQuant program. The labeled DNA probes for human BSP and OPN were cDNA inserts released from B6-5g and OP-10 plasmids respectively (11, 12); for human DMP1, a ~1.4 kbp coding region of exon 6 was employed (13). For the MEPE probe (1.4 kbp) and DSPP probe (2.64 kbp), the labeled probes were the same cDNA inserts that were used in making the recombinant protein (14, 15).

Antibodies

The production of monoclonal antibodies raised against specific SIBLINGs has been previously described (16) and are available from Santa Cruz Biotechnology, Inc. The polyclonal antibodies against BSP, DMP1, MEPE and OPN used in enzyme immunoassays and western blotting have been previously characterized. A polyclonal antibody for DSPP was developed as follows. Recombinant human DSP fragment of DSPP (corresponding to amino acids, T132-D373) was made by PCR of this portion of exon 4 from human genomic DNA using a high fidelity DNA polymerase and oligonucleotides that introduced an in-frame Nde1 site at the 5′ end and an added stop codon plus BamHI site at the 3′ end of the PCR product. The purified PCR product was digested with NdeI and BamHI, ligated into prepared pET-15b (Novagen/EMD Biosciences, LaJolla, CA) bacterial expression vector. The protein made in E. coli was purified on His-Bind resin (Novagen), dialyzed against water, freeze-dried, and four injections of ~250 μg protein each was made in rabbit LF-151 using animal care & use committee-approved protocols at an AAALAC-approved facility. Bleeds were taken every two weeks to produce the antiserum used.

Immunohistochemistry methods

Universal block and antibody diluent were from Dako Inc. (Carpinteria, CA) and biotinylated anti-mouse secondary antibody (Vector BA-2000), alkaline phosphatase streptavidin Vector-AP (AK-5000), and chromogen substrate Vector Red (SK-5100) were obtained from Vector Laboratories (Burlingame, CA) and were employed at dilutions suggested by the manufacturer. Tissue slides were prepared from commercially available human prostate biopsies. In brief, after being fixed in formalin and embedded in paraffin wax, 4 μm sections of tissue were prepared and placed on charged microscope slides. Slides were dried in a tissue-drying oven for 45 minutes at 60°C. Antigen retrieval was carried out after deparaffinization and rehydration by heating slides in 0.01M sodium citrate buffer, pH 6.0 at 99-100° C for 20 minutes. Slides were removed from heat and let stand at room temperature in the same buffer for 20 minutes. Slides were rinsed in Tris-buffered saline, 0.05 M Tris-HCl, pH 7.5, 0.15 M NaCl containing 0.05% Tween 20 (TBS-T) and placed in universal protein block for 20 minutes at room temperature. Slides were then incubated for 45 minutes at room temperature with monoclonal antibodies developed against specific SIBLINGs. Antibodies LFMb25, LFMb31, LFMb21 and LFMb14 were used at 10 μg/ml, 10μg/ml, 0.625μg/ml and 2.5μg/ml to detect the levels of BSP, DMP, DSPP and OPN, respectively. After rinsing in TBS-T, the sections were treated for 30 minutes at room temperature with biotinylated anti-mouse secondary antibody, rinsed with TBS-T, and incubated with alkaline phosphatase-conjugated streptavidin for 30 minutes. After another rinse in TBS-T, color was developed for 20 minutes with Vector red alkaline phosphatase substrate, a substrate system that produces a pink/red reaction product. Sections were briefly counterstained with Vector Hematoxylin, dehydrated and coverslipped. Micrographs were taken using an Axioplan2 microscope, AxioCam MRm camera using AxioVision software (Carl Zeiss Vision, Munchen, Germany).

ELISA sample preparation

SIBLINGs present in human serum are complexed with complement Factor H (17, 18). Taking advantage of the properties of SIBLINGs that they are unstructured (19) and are highly negatively charged, the binding complexes in serum can be disrupted by denaturants to enable subsequent total SIBLING levels to be measured (20). Briefly, serum samples are denatured and disulfide bonds reduced to disrupt complexes, subjected to strong anion exchange chromatography on small disposable columns to remove proteins and reagents that interfere with antibody binding, and then the eluted samples are analyzed by competitive ELISA for each total SIBLING level (20, 21). Curiously about 10% of OPN (that is presumably not bound to complement Factor H) can be measured in plasma by directly assaying the sample with no prior chaotropic treatment. Appropriate plasma samples to measure this “free” OPN in a subset of 40 normal and prostate cancer patient samples were also taken for analysis by competitive ELISA.

ELISA procedures

Greiner high-binding plates were coated with 20 ng/ml recombinant human BSP or OPN, 10 ng/ml MEPE, or 25 ng/ml DSPPxRep (lacking the DPP repeat domain) overnight in 50 mM sodium carbonate buffer, pH 8.0. Recombinant human BSP and OPN were expressed and purified as previously described (8). Recombinant human MEPE was generated and isolated as previously described (21). hDSPPxRep lacking most of the carboxyterminal repetitive domain was made as described (15). Samples and standards were incubated for 2 h with shaking at room temperature with primary antibody. Primary antibodies used were a 1:200,000 dilution of LF-100 rabbit polyclonal antibody (for BSP) or 1:100,000 of LF-124 rabbit polyclonal antibody (for OPN), or a 1:200,000 dilution of LF-155 rabbit polyclonal antibody (for MEPE) or a 1:100,000 dilution of LF-151 (for DSPP) rabbit polyclonal antibody in TBS-T in polypropylene 96 well plates. During the 2 h incubation, antigen-coated plates were blocked with protein-free blocking buffer in TBS (Thermo Fisher Scientific). Antigen-coated plates were then rinsed three times with TBS-T and the antibody-sample solution added to the wells. After incubation for 1 h at room temperature with shaking, the plates were washed three times with TBS-T. A secondary antibody of peroxidase-labeled goat anti-rabbit antibody conjugate (human serum adsorbed Kierkagaard & Perry, Gaithersburg, MD) at 1:2000 was then added and the plates incubated at room temperature for 1h. After three washes with TBS-T, substrate (3,3′,5,5-tetramethylbenzidine microwell peroxidase substrate, BioFX Laboratories) was added and after a 20 min incubation, the color reaction was reacted with stop solution. Absorbance was read at 450 nm and the data analyzed using the program AssayZap (BioSoft, Cambridge, UK). Commercial ELISAs to measure total PSA were obtained from ALPCO Diagnostics (Salem, NH) and the manufacturer's protocol followed.

SDS PAGE and Western blot

Serum samples from normal and prostate cancer subjects were reduced, resolved by SDS- PAGE, transferred to nitrocellulose membrane which were processed for Western blotting as previously described (8). Primary antibody (LF-151 or LFMb21) was used at a 1:2000 dilution while secondary antibody (goat anti-mouse IgG conjugated to horseradish peroxidase) was employed at a dilution of 1:10,000. Following removal of the second antibody solution, the membrane was washed and incubated with SuperSignal West DuraSubstrate (Thermo Fisher Scientific Inc., Waltham, MA). The chemiluminiscent signal was captured, digitized and analyzed using a Kodak GEL Logic 2200 Imaging System (Carestream Health Inc., Rochester, NY)

Results

SIBLING mRNA expression

Previous studies have separately reported elevated expression of BSP, OPN or, most recently, DSPP in prostate tumor paraffin sections. In this study, the expression levels of all five SIBLINGs by prostate tumors were determined using a commercial cancer array containing normalized cDNA separately made from tumor and normal tissue obtained from the same subject. Patient cDNA array was hybridized with 32P-labeled probes for BSP, DMP1, DSPP, MEPE and OPN, the amount of hybridized probe was quantified and the expression levels between normal and tumor tissue were compared (Figure 1). Each patient's “normal” prostate tissue expressed BSP, DMP1, DSPP and MEPE message only at very low levels. Relative to normal tissue expression, the average levels of the tumor-rich areas were elevated at least 9-fold for BSP, DMP1, and DSPP, while MEPE was not significantly elevated. OPN was elevated an average of only 4-fold in tumor extracts due mostly to the apparently higher level of expression of this SIBLING in each patient's “normal” prostate tissue.

Figure 1
SIBLING mRNA expression levels in normal prostate and prostate tumor biopsies. A cancer-profiling array was hybridized with 32P-labeled cDNA probes for SIBLINGs. The arrays contained samples from paired normal and prostate tumor tissue mRNA from individual ...

SIBLING immunohistochemistry

The observation of elevated SIBLING mRNA expression in array samples from subjects with prostate cancer led to the screening of SIBLING proteins in tumor tissue by immunohistochemistry. Serial sections of biopsies from five prostate cancer subjects were reacted separately with monoclonal antibodies against BSP, DMP1, DSPP, MEPE and OPN. The typical results from a single patient can be seen in Figure 2. Positive immunoreactivity, as indicated by the red color, was observed for BSP, DMP1, DSPP and OPN. Consistent with the mRNA expression data, immunoreactive staining for MEPE was not detectable in any of the prostate cancer biopsy sections. In all tumors studied, BSP and OPN immunoreactive staining was visible in the cytoplasm of tumor cells, with diffuse staining of adjacent normal tissue and matrix. DMP1 and DSPP immunoreactive staining was much more localized to the tumor cells in all of the patient samples.

Figure 2
Typical SIBLING immunoreactivities in prostate cancer. A biopsy from a subject with localized nonmetastatic prostate cancer was fixed, paraffin-embedded, and serially sectioned. Sections were then reacted with monoclonal antibodies against (A) BSP, (B) ...

SIBLINGs in serum

Serum samples from a large normal group and a group with prostate cancer were obtained. Samples from the prostate cancer group were obtained at diagnosis and prior to treatment. For the normal group (n = 110), the average age was 65 ± 10 years and BMI values were 23.1 ± 2.6 kg/m2. For the prostate cancer group (n= 102) the average age was 63 ± 5 years and BMI values were 25.0 ± 4.1 kg/m2. Competitive ELISAs for quantitatively determining the levels of total BSP, DSPP, MEPE and OPN were developed and applied. (Unfortunately the ELISA for quantifying DMP1 has recurrent issues with the stability of the recombinant DMP1 protein standard.) The mean levels of BSP, OPN and DSPP protein were all elevated in the cancer patients. The mean values for the normal group versus cancer group respectively were 114 ± 63 versus 222 ± 98 ng/ml for BSP, 242 ± 122 versus 1500 ± 500 ng/ml for DSPP, 93 ± 19 versus 80 ± 11 ng/ml for MEPE, and 353 ± 130 versus 537 ± 170 ng/ml for total OPN. For both BSP and total OPN, there was significant overlap between the distributions of normal and cancer patient serum levels (Figure 3). Mean values in prostate cancer sera were elevated 2-fold for BSP, 6-fold for DSPP, 1.5-fold for total OPN, while MEPE showed no difference between cancer and normal patient sera.

Figure 3
Blood levels of SIBLINGs from normal and prostate cancer individuals. Serum levels of total (A) BSP, (B) DSPP, and (C) total OPN from sera as well as (D) free OPN from plasma from blood of normal subjects (NL) and patients diagnosed with prostate cancer ...

OPN exists in both complement Factor H-bound and “free” forms in plasma and a number of studies have measured OPN directly in plasma without pretreatment of the sample with reducing or chaotropic agents to free the protein from Factor H (22-29). A subset of our normal and prostate cancer subjects (n = 40/group) had blood specimens processed appropriately for measuring free OPN in plasma. The average level of free OPN was 45 ± 20 ng/ml in normal samples and 127 ± 80 ng/ml in prostate cancer samples (Figure 3D). Free OPN accounted for 13 % of total OPN in normal samples and 23% of total OPN in prostate cancer samples. Receiver operator characteristic (ROC) curve profiling of serum SIBLINGs yielded area under the curve (AUC) values that were very significant for DSPP and revealed that free OPN had a better discriminatory power than total OPN (Figure 3 E - H). Cut-off values maximizing sensitivity and specificity for the SIBLINGs were determined to be 142 ng/ml for BSP, 500 ng/ml for DSPP, 358 ng/ml for total OPN and 45 ng/ml for free OPN.

The prostate cancer serum training set samples were evenly distributed between organ confined (pT2) where cancer is localized within the prostate, pT3 when cancer has broken through the capsule of the prostate but is still regional, and lymph node positive (LN+) or seminal vesicle positive (SV+) when the cancer has spread to other tissues (n = 34 for each stage). When the distribution of BSP, OPN and DSPP were profiled by stage using Tukey box plots, discrete patterns were observed (Figure 4). Both BSP and total OPN significantly increased only in late stage disease, while DSPP was elevated at stages pT2, pT3 and LN+/SV+. Free OPN measurements, however, also yielded an average increase in levels across all stages (Figure 4D), in contrast to total OPN. Because PSA is commonly used as a screening tool for prostate cancer, the levels of PSA were also determined and compared with SIBLING values for subjects with prostate cancer (Figure 4 E - H). Because of the non-parametric distribution of PSA, the correlation between SIBLING and PSA was tested by Spearman correlation. The serum levels of total OPN were significantly correlated with total PSA levels (Spearman r = 0.72, p < 0.0001), while the levels of BSP and DSPP were not significantly correlated with PSA values. Free OPN exhibited a significant Spearman correlation with PSA (r = 0.71, p < 0.0001), a value similar to that observed for total OPN. Finally, free and total OPN were also found to be significantly correlated as assessed by Spearman correlation, r = 0.47, p < 0.005.

Figure 4
Blood values for SIBLINGs at specific prostate cancer stages and correlation with PSA levels. The distributions of SIBLING values between cancer stages pT2, pT3, and LN+/SV+ (n = 34 for each stage) were compared for (A) BSP, (B) DSPP, and (C) total OPN ...

Confirmation of elevated serum DSPP levels in prostate cancer serum by western blot analysis

The gene transcript for DSPP yields a precursor protein that is usually cleaved at a highly conserved motif into two distinct proteins, dentin sialoprotein (DSP) and dentin phosphoprotein (DPP) (30). In order to verify elevated levels of DSPP in serum from subjects with prostate cancer and to identify the molecular form(s) of DSPP present, western blot analysis was performed. Serum samples from subjects with prostate cancer were reduced, resolved by SDS-PAGE using 4 to 20% PAGE, transferred to nitrocellulose membranes, and probed with an anti-DSP polyclonal antibody. Sera derived from prostate cancer patients consistently exhibited robust staining and a three band pattern of immunoreactive material, with the largest fragment corresponding to DSP's molecular mass (Figure 5A). A monoclonal antibody against DPP sequences yielded a single major band corresponding to the smallest fragment seen by the polyclonal antibody (Figure 5B). The signal from the western blots was significantly correlated with the ELISA values (Figure 5C).

Figure 5
Western blot analysis of serum for immunoreactive DSPP/DSP. Serum samples were resolved by SDS-PAGE 4 to 20% acrylamide gradient gels following sample reduction. (A) An anti-DSP polyclonal antibody, LF151, was employed as the primary antibody to screen ...

Assay validation

Derived optimal serum value cut-off points for BSP, DSPP and total OPN were applied to a new group of 90 subjects. Samples derived from normal subjects (n = 30, mean age 54.4 ± 7.8 years) exhibited mean values of 111 ± 17 ng/ml for BSP, 346 ± 103 ng/ml for DSPP, 408 ± 87 ng/ml for total OPN, and a mean of 1.2 ± 0.6 ng/ml for PSA. Samples derived from subjects with prostate cancer (n = 60, mean age = 58.0 ± 6.7) possessed serum mean values of 101 ± 17 ng/ml for BSP, 830 ± 339 ng/ml for DSPP, 602 ± 162 ng/ml for total OPN, and 8.4 ± 5.9 ng/ml for PSA. The cut-off value of 142 ng/ml for BSP yielded a sensitivity of 75% and a specificity of 40%, while the cut-off value of 358 ng/ml for total OPN yielded a sensitivity of 92% and a specificity of 30%. The 500 ng/ml cut-off value for DSPP yielded a sensitivity of 90% and a specificity of 100%. Validation set samples were segregated by staging to compare values (Figure 6 A – C). The validation set spanned from stage pT1c to pT2b so late stage disease was not present. Thus, BSP exhibited no increase and the potential negative correlation of DSPP with late stage disease could not be addressed. Stratifying subjects by both serum SIBLING and PSA values revealed that DSPP enabled the clearest distinction between the two groups (Figure 6 D - F). It is of note that the 6 lowest lying samples visible in the DSPP prostate cancer group were also from the patients with the lowest values in both OPN and BSP.

Figure 6
Serum values for SIBLINGs at specific prostate cancer stages and PSA levels in the validation study group. The distributions of SIBLING values between normal (n = 30) and prostate cancer stages pT1c (n = 34), pT2a (n = 13), and pT2b (n = 12) were compared ...

Discussion

Prostate cancer is the most common type of cancer in men in the United States, after skin cancer. Indeed, prostate cancer accounts for over a quarter of all cancers in men and the risk increases with age (1). There has been an increase in the reported incidence of prostate cancer since the early 1980's, most likely due to an increased use of screening using the PSA test (31) although the effectiveness of screening for prostate cancer remains controversial (32).

SIBLINGs, through their interactions with multiple binding partners such as proteases and cell surface receptors, have biological plausibility to be playing an active role in tumor progression (5). Different cancer types exhibit different patterns of individual SIBLING expression (14) as well as serum SIBLING protein levels (20). A number of separate studies have investigated BSP and OPN levels in prostate cancer. Increased BSP expression in prostate carcinoma has been associated with tumor progression and poor prognosis (33). Induced OPN expression and a positive correlation between OPN expression and poor prognosis have also been observed (34, 35). Both BSP and OPN protein levels in serum were found to be elevated in prostate cancer (20). Relative levels of DSPP as measured by immunohistochemistry were associated with the pathological stage and the Gleason score of the tumors (36). The distributions of DMP1 and MEPE in prostate cancer, however, have not been previously reported.

The expression of SIBLINGs by prostate (and breast) carcinoma prompted the hypothesis that osteotropic cancer cells express osteomimetic properties that favor “seeding” in the skeleton by improving their adhesion, proliferation, and/or survival in bone (37). The expression of these ‘bone’ proteins by prostate tumor cells do not necessarily target cell metastasis to bone. It is also possible that transcription factors that regulate SIBLINGs (e.g. RUNX2) produce a mesenchymal phenotype that finds bone a fertile soil for survival. Furthermore, SIBLINGs and their partner MMPs (when known) have recently been shown to be expressed in normal metabolically active ductal epithelial cells of salivary gland (16), kidney (38). Normal sweat gland expressed all but MEPE (6). Therefore, it is no longer necessary to invoke an epithelial-mesenchymal conversion hypothesis when considering SIBLING expression in epithelially derived tumors.

In the current study, the total serum levels of BSP and OPN were found to be significantly elevated only in late stage prostate cancer. While free OPN levels in plasma increased significantly from pT2 through LN+/SV+ stages, the positive association of both free (plasma) and total (serum) OPN levels with serum PSA levels may be indicative of reactive processes of inflammation and not necessarily direct tumor pathology (39, 40). While there was significant overlap between the levels of both BSP and OPN in sera of normal and prostate cancer patients, the serum DSPP levels uniquely showed minimal overlap.

DSPP was initially characterized through the isolation of one of its cleavage products from dentin, DPP (41). Subsequent cloning of the gene revealed that the transcript encodes the amino-terminal dentin sialoprotein (DSP) and dentin phosphoprotein (DPP) (30). DSP has been hypothesized to be an important factor in dentinogenesis, while DPP may be involved in dentin biomineralization (42). Elevated DSPP expression has been observed in a subset of breast, oral, and lung cancers (14) as well as in prostate cancer (36). The rabbit polyclonal antibody recognizes DSP-related fragments while the monoclonal detects DPP sequence containing fragments. Because it contains the highly conserved MQXDDP motif that has been shown in DMP1 to be involved in proteolytic processing, it has been hypothesized that the same tolloid-related proteases (particularly BMP1) cleave DSPP into DSP and DPP (43). The subsequent processing of DSP into additional fragments by other proteases is possible. Proteolytic processing of DSPP by MMP-2, MMP-20 and kallikrein-related peptidase 4 (KLK4) has been reported (44) and upregulation of both MMP-2 and KLK4 in prostate cancer have been observed (45, 46).

Observations of our current study are consistent with SIBLING levels being associated with tumor progression and suggest that SIBLINGs, particularly DSPP, may be developed as informative serum biomarkers. The lack of correlation of DSPP serum levels with PSA values suggests that the two markers might complement each other. Indeed, as shown in the validation group, segregating samples as a function of both PSA and DSPP (Figure 6) removed overlap between the normal and cancer group, thereby increasing sensitivity and specificity. The current study also provides evidence in support of future studies screening a large patient population as well as testing baseline value association with disease outcome and response to treatment to determine the utility of this new serum biomarker for prostate cancer detection.

Acknowledgments

This research was supported in part by NIH grants CA 113865 (N.S.F.).

Footnotes

Statement of Translational Relevance. Prostate cancer is the leading cancer diagnosed among men in the United States. The development of informative serum marker(s) to augment PSA measures would provide clinicians with greater information to enable assignment of individuals with prostate cancer to groups at different risks for cancer progression. A new marker that tracks with PSA might not be expected to yield any new information, whereas a marker with a high degree of sensitivity and specificity that tracks with disease but not PSA (such as the SIBLING DSPP) might be more informative. The work has the potential to benefit individuals with prostate cancer across the spectrum from early detection to disease progression monitoring and modulating therapy.

Literature Cited

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. [PubMed]
2. Maattanen L, Hakama M, Tammela TL, et al. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer. 2007;96:56–60. [PMC free article] [PubMed]
3. Perrotti M. Understanding PSA and prostate cancer risk assessment. N J Med. 2001;98:35–8. [PubMed]
4. Altwein J, Ekman P, Barry M, et al. How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. Urology. 1997;49:66–76. [PubMed]
5. Bellahcene A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008;8:212–26. [PMC free article] [PubMed]
6. Ogbureke KU, Fisher LW. SIBLING expression patterns in duct epithelia reflect the degree of metabolic activity. J Histochem Cytochem. 2007;55:403–9. [PubMed]
7. Fisher LW, Jain A, Tayback M, Fedarko NS. Small Integrin Binding LIgand N-linked Glycoprotein (SIBLING) gene family expression in different cancers. Clin Can Res. 2004;10:8501–11. [PubMed]
8. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. Faseb J. 2004;18:734–6. [PubMed]
9. Jain A, Fisher LW, Fedarko NS. Bone sialoprotein binding to matrix metalloproteinase-2 alters enzyme inhibition kinetics. Biochemistry. 2008;47:5986–95. [PMC free article] [PubMed]
10. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387–92. [PubMed]
11. Fisher LW, McBride OW, Termine JD, Young MF. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem. 1990;265:2347–51. [PubMed]
12. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986;83:8819–23. [PubMed]
13. Hirst KL, Ibaraki-O'Connor K, Young MF, Dixon MJ. Cloning and expression analysis of the bovine dentin matrix acidic phosphoprotein gene. J Dent Res. 1997;76:754–60. [PubMed]
14. Fisher LW, Jain A, Tayback M, Fedarko NS. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res. 2004;10:8501–11. [PubMed]
15. de Vega S, Iwamoto T, Nakamura T, et al. TM14 is a new member of the fibulin family (fibulin-7) that interacts with extracellular matrix molecules and is active for cell binding. J Biol Chem. 2007;282:30878–88. [PubMed]
16. Ogbureke KU, Fisher LW. Expression of SIBLINGs and their partner MMPs in salivary glands. J Dent Res. 2004;83:664–70. [PubMed]
17. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem. 2000;275:16666–72. [PubMed]
18. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem. 2002;277:13700–8. [PubMed]
19. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280:460–5. [PubMed]
20. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7:4060–6. [PubMed]
21. Jain A, Fedarko NS, Collins MT, et al. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab. 2004;89:4158–61. [PubMed]
22. Bautista DS, Saad Z, Chambers AF, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem. 1996;29:231–9. [PubMed]
23. Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006;12:3337–43. [PubMed]
24. Petrik D, Lavori PW, Cao H, et al. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol. 2006;24:5291–7. [PubMed]
25. Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate. 2007;67:330–40. [PubMed]
26. Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol. 2007;133:643–52. [PubMed]
27. Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782–9. [PMC free article] [PubMed]
28. Kadkol SS, Lin AY, Barak V, et al. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci. 2006;47:802–6. [PMC free article] [PubMed]
29. Martinetti A, Bajetta E, Ferrari L, et al. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer. 2004;11:771–9. [PubMed]
30. MacDougall M, Simmons D, Luan X, Nydegger J, Feng J, Gu TT. Dentin phosphoprotein and dentin sialoprotein are cleavage products expressed from a single transcript coded by a gene on human chromosome 4. Dentin phosphoprotein DNA sequence determination. J Biol Chem. 1997;272:835–42. [PubMed]
31. Pashayan N, Powles J, Brown C, Duffy SW. Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing. Br J Cancer. 2006;95:398–400. [PMC free article] [PubMed]
32. Andriole GL, Grubb RL, 3rd, Buys SS, et al. Mortality Results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med. 2009 [PMC free article] [PubMed]
33. Waltregny D, Bellahcene A, Van Riet I, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst. 1998;90:1000–8. [PubMed]
34. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2006;118:2255–61. [PubMed]
35. Khodavirdi AC, Song Z, Yang S, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 2006;66:883–8. [PubMed]
36. Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V, Bellahcene A. Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer. 2006;118:850–6. [PubMed]
37. Koeneman KS, Yeung F, Chung LW. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999;39:246–61. [PubMed]
38. Ogbureke KU, Fisher LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs) Kidney Int. 2005;68:155–66. [PubMed]
39. Banu NA, Azim FA, Kamal M, Rumi MA, Barua AR, Khan KH. Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value. Bangladesh Med Res Counc Bull. 2001;27:79–83. [PubMed]
40. Loeb S, Gashti SN, Catalona WJ. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA) Urol Oncol. 2009;27:64–6. [PubMed]
41. Veis A, Perry A. The phosphoprotein of the dentin matrix. Biochemistry. 1967;6:2409–16. [PubMed]
42. Qin C, Baba O, Butler WT. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med. 2004;15:126–36. [PubMed]
43. Steiglitz BM, Ayala M, Narayanan K, George A, Greenspan DS. Bone morphogenetic protein-1/Tolloid-like proteinases process dentin matrix protein-1. J Biol Chem. 2004;279:980–6. [PubMed]
44. Yamakoshi Y, Hu JC, Iwata T, Kobayashi K, Fukae M, Simmer JP. Dentin sialophosphoprotein is processed by MMP-2 and MMP-20 in vitro and in vivo. J Biol Chem. 2006;281:38235–43. [PubMed]
45. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 2004;64:2365–70. [PubMed]
46. Zeng H, Xiao Y, Lu G, Chen Y. Immunohistochemical studies of the expression of matrix metalloproteinase-2 and metalloproteinase-9 in human prostate cancer. J Huazhong Univ Sci Technolog Med Sci. 2003;23:373–4. 9. [PubMed]